BIOA
Price
$21.79
Change
-$2.56 (-10.52%)
Updated
Jul 13 closing price
Capitalization
968.63M
29 days until earnings call
Intraday BUY SELL Signals
HROW
Price
$41.81
Change
-$0.67 (-1.58%)
Updated
Jul 13 closing price
Capitalization
1.56B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIOA vs HROW

BIOA vs HROW Comparison Chart in %
View a ticker or compare two or three
VS
BIOA vs. HROW commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a StrongBuy and HROW is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (BIOA: $21.78 vs. HROW: $41.81)
Brand notoriety: BIOA and HROW are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOA: 58% vs. HROW: 17%
Market capitalization -- BIOA: $968.63M vs. HROW: $1.56B
BIOA [@Pharmaceuticals: Generic] is valued at $968.63M. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.56B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOA’s FA Score shows that 2 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • BIOA’s FA Score: 2 green, 3 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, BIOA is a better buy in the long-term than HROW.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOA’s TA Score shows that 5 TA indicator(s) are bullish while HROW’s TA Score has 4 bullish TA indicator(s).

  • BIOA’s TA Score: 5 bullish, 5 bearish.
  • HROW’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BIOA is a better buy in the short-term than HROW.

Price Growth

BIOA (@Pharmaceuticals: Generic) experienced а -12.30% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -6.94% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

Reported Earning Dates

BIOA is expected to report earnings on Aug 12, 2026.

HROW is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.56B) has a higher market cap than BIOA($969M). BIOA YTD gains are higher at: 64.664 vs. HROW (-14.673). HROW has higher annual earnings (EBITDA): 32.5M vs. BIOA (-89.21M). BIOA has more cash in the bank: 383M vs. HROW (94.6M). BIOA has less debt than HROW: BIOA (4.03M) vs HROW (301M). HROW has higher revenues than BIOA: HROW (269M) vs BIOA (10.3M).
BIOAHROWBIOA / HROW
Capitalization969M1.56B62%
EBITDA-89.21M32.5M-274%
Gain YTD64.664-14.673-441%
P/E Ratio1.37N/A-
Revenue10.3M269M4%
Total Cash383M94.6M405%
Total Debt4.03M301M1%
FUNDAMENTALS RATINGS
BIOA vs HROW: Fundamental Ratings
BIOA
HROW
OUTLOOK RATING
1..100
8584
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
5650
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3443
P/E GROWTH RATING
1..100
611
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOA's Valuation (32) in the Chemicals Specialty industry is somewhat better than the same rating for HROW (75) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (50) in the Pharmaceuticals Other industry is in the same range as BIOA (56) in the Chemicals Specialty industry. This means that HROW’s stock grew similarly to BIOA’s over the last 12 months.

HROW's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as BIOA (98) in the Chemicals Specialty industry. This means that HROW’s stock grew similarly to BIOA’s over the last 12 months.

BIOA's Price Growth Rating (34) in the Chemicals Specialty industry is in the same range as HROW (43) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to HROW’s over the last 12 months.

BIOA's P/E Growth Rating (6) in the Chemicals Specialty industry is in the same range as HROW (11) in the Pharmaceuticals Other industry. This means that BIOA’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOAHROW
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 20 days ago
83%
Bullish Trend 26 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BIOA
Daily Signal:
Gain/Loss:
HROW
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GXPE33.081.01
+3.14%
Global X PureCap MSCI Energy ETF
AQWA19.28N/A
N/A
Global X Clean Water ETF
MMMA25.49N/A
N/A
NYLI MacKay Muni Allocation ETF
IBDY25.40-0.11
-0.43%
iShares iBonds Dec 2033 Term Corp ETF
DHY1.73-0.04
-2.26%
Credit Suisse High Yield

BIOA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOA
1D Price
Change %
BIOA100%
-10.50%
UPC - BIOA
43%
Loosely correlated
-15.56%
AMLX - BIOA
27%
Poorly correlated
-2.03%
TKNO - BIOA
26%
Poorly correlated
+0.93%
COLL - BIOA
25%
Poorly correlated
-1.16%
HROW - BIOA
23%
Poorly correlated
-1.58%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMLX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-1.58%
AMLX - HROW
34%
Loosely correlated
-2.03%
AQST - HROW
30%
Poorly correlated
-1.46%
AMRX - HROW
29%
Poorly correlated
+1.00%
RMTI - HROW
27%
Poorly correlated
+1.07%
SIGA - HROW
26%
Poorly correlated
+0.56%
More